Tumors of the central nervous system (CNS) are the most common type of solid tumors in children. 1 During recent decades, progress in neurosurgery and improved CNS-directed radiation therapy in combination with chemotherapy have contributed to a large increase in the overall 5-year survival rate, 2 which now approaches 60% 
in the Nordic countries. 3 Studies nevertheless indicate that this group of survivors faces substantial long-term morbidity, including second primary cancers, 4,5 neurocognitive difficulties, 6 and chronic medical conditions such as endocrine disorders 7, 8 and cerebrovascular diseases. [8] [9] [10] In addition, CNS tumor survivors are at high risk for late mortality due to causes other than relapse of the primary tumor. 11 A tumor in the brain often distorts or destroys the surrounding normal brain tissue, and surgical resection, which is the main therapy for most primary brain tumors, 12 may cause irreversible damage, with severe consequences for the survivor. 13 Therefore, several of the neurologic disorders that can affect survivors' functioning and well-being throughout life, such as epilepsy, paralytic syndromes, and hydrocephalus, may appear at the time of tumor diagnosis, or even before. There are no large population-based studies of survivors of childhood CNS tumors that give a comprehensive, detailed overview of serious neurologic disorders that necessitate inpatient care before and after the tumor diagnosis. In particular, no information is available on neurologic sequelae that first become symptomatic during middle age or senescence, when the brain and nervous system are generally more vulnerable. The aim of the present study was to determine the lifetime risk for cause-specific hospitalization for neurologic disorders in a large cohort of patients with a CNS tumor diagnosed in childhood between 1943 and 2008.
Methods

Patient and Comparison Cohorts
The study is part of the collaborative study on Adult Life after Childhood Cancer in Scandinavia (ALiCCS; www. aliccs.org). Details of the ALiCCS study have been given elsewhere. 14 In brief, the basic childhood cancer cohort comprised 33 576 individuals with cancer diagnosed before they were age 20 years in the periods in Denmark, 1971 -2008 in Finland, 1955 -2008 in Iceland, and 1958 -2008 in Sweden (Supplementary Figure S1) . The individuals included were alive on the date at which the national population registers of each country became operational with all the required variables (1955) (1956) (1957) (1958) (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) . From this date, all residents were assigned a unique personal identification number, which allows accurate linkage of information among registers. The cancer registries are nationwide, with diagnoses reported from multiple sources to secure virtually 100% coverage. [15] [16] [17] [18] Over time, cancers have been notified according to the International Classification of Diseases, 7th-10th revisions (ICD-7-10), or the ICD for Oncology, 1st-3rd editions (ICD-O1-O3).
For each childhood cancer patient, we randomly selected 5 comparison subjects from the population registers of the 4 countries, who were alive on the date of cancer diagnosis of the corresponding patient, of the same sex, age, and country, and without a diagnosis of childhood cancer. Fewer than 5 comparison subjects were available for 157 patients, leaving 167 712 individuals for study (Supplementary Figure S1) . We obtained information on the vital status and migration of both patients and comparisons.
The childhood cancer cohort used in the present study was a subset of the original cohort and comprised 7582 individuals with a primary tumor located in the CNS (ICD-7 codes 193.0-2, 195.3-4; ICD-8/9 codes 191.0-9, 192.0-3, 194.3-4; ICD-O1 codes 191.0-9, 192.0-9, 194.3-4; ICD-10 and ICD-O2/3 codes C70.0-9; C71.0-9; C72.0-9; C75.1-3). Before linkage to the national hospital registers, we excluded 79 patients in whom an additional primary cancer was diagnosed in childhood. We also excluded 488 patients and 780 comparison subjects who had died or emigrated before the start of the hospital registers (Denmark, 1977; Finland, 1983; Iceland, 1999 ; and Sweden, stepwise inclusion of counties in 1964-1987 and nationwide since 1987). These exclusions resulted in cohorts of 7015 CNS tumor patients and 166 932 comparisons subjects.
Hospital Contacts for Neurologic Disorders
The national hospital registers contain information on virtually all nonpsychiatric hospital admissions in the respective countries. Registration is mandatory and is recorded by the treating physician. Each hospital admission initiates a record, which includes the personal identification number, admission and discharge dates, a primary discharge diagnosis, and supplementary diagnoses coded according to ICD-7-10. 19, 20 Linkage to the hospital registers showed that 26 CNS tumor patients and 274 comparison subjects had been admitted for a chromosomal abnormality (ICD-8 codes: 759.3−759.5, ICD-9: 758, and ICD-10: Q90−Q99). These individuals were excluded, leaving 6989 CNS tumor
Importance of the study
This study estimated both relative and absolute risks for neurologic outcomes in the largest cohort of children diagnosed with a CNS tumor. Using a population-based design, we showed that 5-year survivors had a notably increased risk for a wide range of neurologic disorders, including epilepsy, hydrocephalus, paralytic syndromes, infectious diseases of CNS, disorders of cranial nerves, and degenerative diseases of the nervous system, which have not been reported before. Epilepsy was the most common disorder, and we were able to show that the survivors already had an increased risk several years before their cancer diagnosis. The risks reported in this study add to the burden of late complications. As most long-term survivors are not followed in specialized late-effect clinics, primary care physicians and medical specialists working outside the late-effect area should be aware of the growing group of survivors who are at increased risk for neurologic disorders throughout their lives.
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patients and 166 658 comparisons for study. Of these, 4858 patients (69.5%) and 152 159 comparisons (91.3%) were followed for 5 years or longer after the CNS tumor diagnosis (Supplementary Figure S1) . For all study subjects, we identified hospital admissions that resulted in primary or supplementary discharge diagnoses of relevant neurologic disorders in these sections of the ICD (ICD-7 codes 057, 340−369, 780, and 791; ICD-8: 036, 290, 306, 320−358, 780 and 791; ICD-9: 036, 290, 320−359, 780.5, 784.0, and 997.0; ICD-10: A39, F00−F03, F26 and G00−G99). We did not include cerebrovascular disease, as these outcomes have already been reported. 9 The study protocol was approved by the national authorities 
Statistical Analysis
All 6989 children with a CNS tumor were followed for a first hospital admission for epilepsy, a paralytic syndrome, and/or hydrocephalus from their date of birth until tumor diagnosis. They were also followed for a first admission or a first readmission to hospital for one or more of these disorders from date of tumor diagnosis until date of death or 5 years after the date of diagnosis, whichever occurred first. The patients who were still alive at this time were included in the main analysis of 5-year survivors. We further followed up these patients for a first hospital admission for any type of neurologic disorder, irrespective of previous admissions. Follow-up started 5 years after tumor diagnosis or at the start of the national hospital registers, whichever occurred latest, and ended on the date of death, emigration, or end of study in 2008 (Iceland), 2009 (Sweden), 2010 (Denmark), and 2012 (Finland), whichever occurred first. Follow-up also ended if a second primary cancer in a survivor or a first primary cancer in a comparison subject was diagnosed after the age of 20 years.
In the cohort of 5-year survivors, we analyzed the risk for a first hospital admission for a neurologic disorder of any type in each of 9 main diagnostic categories and for a set of diagnostic subcategories and diagnoses within the main diagnostic categories. If cohort members had been admitted to hospital more than once for a disorder in one of the categories defined above, only the first admission was retained. The diagnostic categories of ICD-7-9 were adapted to those of the ICD-10 as far as possible.
The observed numbers of first hospital admissions for a given category-prior (defined as the period from birth to one month before tumor diagnosis), synchronously (one month before to one month after diagnosis), and after (one month after the diagnosis or later)-were compared with expected numbers derived from the appropriate country-, sex-, age-, and calendar periodic-specific admission rates of the comparison cohort. Standardized hospitalization rate ratios (RRs) for each disease category, taken as the ratio of observed to expected hospital admissions for each defined disease entity, were then estimated. The 95% confidence intervals (CIs) were computed from Fieller's theorem on the assumption that the observed numbers of hospital admissions followed a Poisson distribution. 21 Absolute excess risks (AERs) (ie, the additional risks of survivors for hospitalization for a neurologic disorder) were derived from the difference between the observed and expected hospitalization rates per 1000 person-years, with corresponding 95% CIs. The analyses were stratified by sex, country (Denmark, Finland, Iceland, Sweden), time since diagnosis (5-9, 10-19, ≥20 y), attained age (5-9, 10-19, 20-29, 30-39, 40-49, 50-59, ≥60 y), tumor type (ependymoma, astrocytoma and other gliomas, embryonal tumors, other specified and unspecified CNS tumors) and radiation therapy (yes, no). Information on radiation therapy was available for 2390 five-year survivors from Denmark and Finland (49.2 % of all 5-year survivors).
We estimated the cumulative incidence stratified by age at cancer diagnosis (0-4, 5-9, 10-14, 15-19 y) and era of cancer diagnosis (1960-1974, 1975-1990, 1991-2007) for any first hospital admission for a neurologic disorder taking the competing risk for death into account. The cumulative incidence was also calculated by subtype of CNS tumor for the 3 eras of cancer diagnosis with age as the underlying time scale. In addition, the cumulative burden of neurologic hospitalizations was estimated by calculating the mean number of (1) first and (2) all hospitalizations, including readmissions, that a survivor or population comparison has by a given timepoint, with death as a competing risk. 22 Finally, we conducted a subanalysis including those study participants for whom we had complete follow-up in the hospital registries. All calculations were performed with SAS software version 9.4, except the cumulative incidence function and mean cumulative count, which were calculated in R version 3.4.1 (packages "etm, " "survival, " and "ggplot2"). 23 
Results
All Children with Diagnosis of CNS Tumor
Linkage of the 6989 CNS tumor patients to the hospital registers showed that 1315 (18.8%) had had a first hospital admission for epilepsy, a paralytic syndrome, and/ or hydrocephalus before or synchronously with the tumor diagnosis, while 790 (11.3%) had had a first admission for these disorders in the period 1 month to 4 years after diagnosis (Table 1) . Table 2 gives the corresponding RRs for cause-specific admissions prior to or synchronously with the CNS tumor diagnosis. Highly elevated risks for these disorders were already seen years before cancer diagnosis.
Five-Year Survivors
The main analysis of late neurologic outcomes included 4858 CNS tumor patients who were alive 5 years after diagnosis. This subgroup, which is further characterized in Supplementary Table S1, was followed in the hospital registers for 76 061 person-years (median, 13 y; range, 0-42 y). During this time, 1309 patients (26.9%) were ever hospitalized for a neurologic disorder, while 92.4 (1.9%) were expected, yielding a highly increased overall RR of 14.2 (95% CI: 13.3-15.1) ( Table 3 ). The RRs of men and women First readmission after tumor diagnosis for one of the 3 neurological disorders in patients with first admission for the disorder before or synchronous with the tumor diagnosis.
c First readmission after the tumor diagnosis for one of the 3 neurological disorders in patients with first admission for the disorder 1 month to 5 years after tumor diagnosis.
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were 15.7 (95% CI: 14.5−17.1) and 12.7 (95% CI: 11.6−13.9), respectively. The risk for a first hospital admission for a neurologic disorder was particularly high 5-9 years after diagnosis (RR: 32.9, 95% CI: 30.2−35.8) but remained markedly increased 20 or more years after diagnosis. The overall AER of survivor of a CNS tumor in childhood was 20 hospitalizations for a neurologic disorder of any type per 1000 persons per year. When the analysis was stratified by subtype of CNS tumor, highest RRs were seen for ependymoma (RR: 19.2, 95% CI: 16.2-22.7) and embryonal tumors (RR: 18.7, 95% CI: 15.4-22.8) followed by other specified and unspecified CNS tumors (RR: 14.4, 95% CI: 13.0-16.0) and astrocytoma and other gliomas (RR: 12.9, 95% CI: 11.9-14.0). The RR for survivors who had received radiation therapy as part of their cancer treatment was 18.2 (95% CI: 16.1-20.5), while the risk was 13.2 (95% CI: 11.9-14.6) among those who were not irradiated.
We stratified the 5-year survivor cohort by age at CNS tumor diagnosis and calculated the cumulative incidence for hospitalization for a neurologic disorder of any type (Fig. 1) . Survivors of tumors diagnosed when they were ages 0-4 years had the highest cumulative incidence, 48.1% already being affected before the age of 10 years and 72.8% being affected by the age of 60 years. We also calculated the cumulative incidence by era of diagnosis (1960-1974, 1975-1990, and 1991-2007) to elucidate if there had been an increase or a decrease in neurologic complications over time. The cumulative incidence for a hospitalization for any neurologic disorder was almost identical in the 2 latest eras of diagnosis, both at age 20 years (1975-1990 : 62%, 95% CI: 47-77; 1991-2007: 61%, 95% CI: 51-71) and 40 years (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) : 70%, 95% CI: 57-82; 1991-2007: 71%, 95% CI: 63-79) compared with the population comparisons. A slightly lower cumulative incidence was seen for the earliest era of diagnosis (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) , with 51% of the survivors (95% CI: 39-66) being hospitalized at age 20 years and 62% (9% CI: 51-72) at age 40 years (data not shown). We also calculated the cumulative incidence for the 3 eras of diagnosis by subtype of CNS tumor (see Supplementary Figure S2 ). The pattern for all the subtypes was similar, with the vast majority of the first hospitalizations observed in survivors under the age of 20 years. Five-year survivors of embryonal tumors had a lower cumulative incidence in all treatment periods; however, the confidence limits were broad for all the subtypes. Table 4 gives the estimated relative and absolute risks of all 5-year survivors for admission to hospital for a neurologic disorder in each of the 9 main diagnostic categories and a selected set of subcategories and diagnoses. Significantly increased RRs were found for a first hospital admission for a diagnosis in one of the main diagnostic categories, except for demyelinating diseases. The risk was highest for the main diagnostic category, which included hydrocephalus (RR: 62.0, 95% CI: 54.1-71.0), followed by the categories of paralytic syndromes (RR: 40.3, 95% CI: 33.1-49.2), episodic and paroxysmal disorders (RR: 13.4, 95% CI: 12.3-14.5), and degenerative diseases (RR: 11.4, 95% CI: 6.7-19.4). The AER was highest for the main diagnostic category of episodic and paroxysmal disorders (109 first admissions per 10 000 survivors per year), followed by hydrocephalus and other disorders of the nervous system (75), and paralytic syndromes (27) ; these 3 main diagnostic categories constituted 90.9% of the excess hospitalizations for neurologic disorders among survivors of a childhood CNS tumor.
Among the 4858 five-year survivors, 685 (14.1%) were hospitalized for epilepsy, 203 (4.2%) for a paralytic syndrome, and 463 (9.5%) for hydrocephalus. However, several of the survivors had also been hospitalized for these disorders before follow-up started 5 years after cancer Table S2 ). The RRs for epilepsy and paralytic syndromes were almost identical for survivors of astrocytoma and other gliomas and embryonal tumors. All survivors had extremely high RRs for hydrocephalus. Survivors who were irradiated as a part of their cancer treatment had high risks for being hospitalized for a disorder in the main diagnostic groups (except demyelinating diseases of CNS), and for epilepsy and hydrocephalus (Supplementary Table S3 ). All risks were lower among survivors with no radiation therapy. 
Supplementary Figure S3 shows the cumulative burden of all first hospitalizations for different neurologic disorders (3A) and for all hospitalizations, including readmissions (3B). The neurologic burden was much higher when all hospitalizations are summarized, and not just the first hospitalization experienced by the survivors.
Discussion
This large population-based cohort study of 6989 survivors of a CNS tumor in childhood, of whom 4858 survived 5 years or more, showed that they were strongly affected by a wide range of serious neurologic disorders in the months and years up to the cancer diagnosis, during the diagnostic investigation, and after. In particular, we found high risks for epilepsy, hydrocephalus, and paralytic syndromes, which, combined, affected 2515 individuals, representing 36% of all patients. We also observed a clearly increased risk for degenerative diseases of the nervous system later in life.
The improvements in survival of childhood cancer patients in recent decades have been substantial, but survivors of a CNS tumor are among those at highest risk for physical and cognitive sequelae. The main focuses of previous studies of late complications have been on endocrine dysfunction, subsequent neoplasms, neurocognitive and neurosensory complications, and motor dysfunction. 2,24-28 To our knowledge, no larger population-based study of CNS tumor patients has addressed the full diagnostic range of severe neurologic complications both before and after tumor diagnosis and treatment. The risk for hospital-acquired morbidity, including the overall risk for neurologic disorders, was examined in 3 larger cohort studies of 5-year survivors of cancer diagnosed in childhood, adolescence, and young adulthood (0-24 y), in Scotland, British Columbia (Canada), and the North American Childhood Cancer Survivor Study (CCSS). [29] [30] [31] The overall risk for a hospital admission for any neurologic disorder among survivors of a childhood CNS tumor was 15.5 (95% CI: 13.2-18.3) in the Scottish study, 29 17 .8 (95 % CI: 11.7-27.2) in the Canadian study, 30 and 22.2 (95% CI: 19.1-25.6) in the CCSS. 31 The risk estimate from the CCSS is somewhat higher than the RR of 14.2 (95% CI: 13.3-15.1) found in our study. As our Nordic study started in 1943, it includes a larger fraction of person-years for older people, who have lower relative risks due to generally higher background rates of neurologic conditions, resulting in a lower overall RR than in the CCSS, which had a more recent start of follow-up.
Epilepsy was the most common reason for hospitalization both before and after diagnosis of a CNS tumor. More than one third of the 5-year survivors had had a first admission for epilepsy either before the tumor diagnosis or during the first 5 years after, and the risk for hospitalization for this condition was also highly increased in the 5-year survivors, with an overall RR of 28.7 (95% CI: 26.0-31.6). In a CCSS-based study of self-reported neurologic Exp.
Inflammatory and infectious diseases of CNS
G00−G09 NeuroOncology late effects among 1886 five-year survivors of a CNS malignancy, the risk for a late onset seizure was 12.7 (95% CI: 10.7-21.2) in comparison with siblings, with a cumulative incidence of 41% 30 years after the primary cancer diagnosis. 28 Radiation to the brain, with the exception of posterior fossa, increased the risk for seizures, which is in line with our results of a higher risk for epilepsy among survivors who had received radiation therapy.
Hydrocephalus is a frequent, well-known complication of an expanding brain tumor, 12 as seen in our study by the exceptionally high RR of 12 870 in the months around diagnosis of the tumor; however, the risk for admission to hospital for hydrocephalus remained increased even decades after the diagnosis. The cause may be relapse of the original tumor, a new primary brain tumor, for which survivors are at increased risk, 25 or a shunt failure. 32 Hydrocephalus is a major complication, as its long-term effects can include cognitive dysfunction, epilepsy, chronic headache, and depression, in addition to unemployment and dependence on care. 33 In our study, the risk for paralytic syndromes was high before, around, and after the diagnosis of a CNS tumor. The overall RR of the 5-year survivors was 40.3 (95% CI: 33.1-49.2), which is substantially higher than that of 12.5 (95% CI: 8.9-17.6) reported from the CCSS. 2 We included all survivors who had been admitted to hospital 5 or more years after the tumor diagnosis, irrespective of a previous history of paralysis, while the CCSS included only paralytic events in 5-year survivors with no previous history of paralysis. Some of the paralytic syndromes that first occurred later in life may have been caused by a stroke, as survivors treated with cranial irradiation are at increased risk for apoplexy 10 ; however, a paralytic syndrome and apoplexy were diagnosed during the same hospitalization in only 5 of the 203 survivors with paralysis in our study.
We found highly increased risks for hospitalization for dementia, Alzheimer disease, and other degenerative diseases of the CNS among survivors who received radiation as part of their cancer treatment. According to our knowledge, this has not been reported previously. In a study of memory impairment in adult survivors of acute lymphoblastic leukemia in the St Jude Lifetime Cohort Study, survivors who received 24 Gy of cranial radiation therapy had reduced cognitive status and memory, consistent with a diagnosis of mild cognitive impairment. 34 As this has been linked to later development of dementia, 35 it is conceivable that cranial radiation therapy in children causes cognitive changes that lead to dementia over time, although a longterm effect of hydrocephalus is another likely explanation.
The 5-year survivors in our study were diagnosed in a time span of more than 60 years, thus the children have received different treatments depending on time of diagnosis. Advances in diagnostic techniques as well as progress in neurosurgery, radiation therapy, and incorporation of chemotherapy have all had a major impact on disease control and the outcomes in the survivors. 36 Despite the advances, we did not observe any decrease in the cumulative incidence of neurologic hospitalizations from the earliest treatment period in the 1960s and 1970s to the latest period in 1990 to 2007. During the most recent treatment periods, more patients become 5-year survivors, including children in the poor diagnostic groups. These patients Absolute excess risk per 10 000 person-years. Table 4 Continued receive aggressive treatment, which is expected to contribute to a high burden of late complications. Further studies investigating specific subtypes of CNS tumors in relation to individual cancer treatment are warranted to evaluate the effect of the treatment advances over time on the risk for neurologic complications.
As the type and degree of late effects are closely linked to type of cancer treatment, a major limitation of our study is the absence of information on surgical procedures, doses of radiation treatment, and chemotherapy for individuals in the Nordic registries. To overcome this limitation, the ALiCCS cohort studies, with estimates of absolute and relative risks for a wide range of late effects, will be supplemented by case-cohort studies of selected outcomes, including epilepsy, with treatment data abstracted from the medical records. 14 The prospective nature of our study, with registration of key information on CNS tumors in advance and independently of registration of neurologic outcomes, virtually complete national cancer registries, and no loss to followup reduce the likelihood of biases due to selection of study participants or differential reporting of neurologic outcomes. Further strengths include the unbiased identification of population comparisons (instead of siblings) and use of neurologic discharge diagnoses reported by treating physicians as the medically verified outcomes. Although we cannot exclude the possibility that our risk estimates were affected by better medical surveillance of the survivors than of the population comparisons, surveillance bias would preferentially affect less well defined medical problems, such as migraine, headache, and sleep disturbances, and not severe neurological conditions requiring hospitalization.
We might have missed an unknown fraction of hospital admissions of study participants with a CNS tumor diagnosed before the start of the hospital registers; however, a sensitivity analysis only of those study subjects for whom a full hospital history was available changed the 
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overall relative risk estimate for neurologic disorders only marginally (ie, from 14.2 to 14.4). As we used diagnoses assigned by hospital physicians as markers of outcome to ensure the validity of the diagnostic information, we could not include less severe conditions that are treated in the primary health care system. Although our study therefore does not give the full picture of the survivors' neurologic disease burden, this limitation also applies to the comparison subjects, and the validity of the estimates of risk was probably little affected.
In conclusion, we found an increased risk for a wide range of neurologic disorders among survivors diagnosed with a CNS tumor in childhood, including epilepsy, hydrocephalus, paralytic syndromes, infectious diseases of CNS, disorders of cranial nerves, and degenerative diseases of the nervous system. The risk for epilepsy was already increased from birth and up to 2 years before the CNS tumor was diagnosed, indicating a lifelong increased risk for neurologic disorders from birth persisting into adulthood and senescence. The risks reported in this study add to the burden of late complications in the survivors demonstrated in previous studies. Knowledge of the diseasespecific hospitalization pattern among these survivors may contribute to improving health care planning in terms of long-term follow-up care and management of excess morbidity.
As the oldest survivors in our study were treated by surgery alone or in combination with radiotherapy, these survivors are different from children who were diagnosed more recently with a CNS tumor. Thus, further studies are needed to include longer follow-up of the younger survivors to assess whether the risk for neurologic complications differs due to changes in treatment. In addition, further research on risk stratification is important to identify those survivors at highest risk for late neurologic complications who will benefit from early prevention strategies.
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